Sponsor content
162 result(s) found, displaying 1 to 10
-
Australian public assessment report (AusPar)Rapiblyk is indicated for short‑term control of supraventricular tachycardia and ventricular rate in atrial fibrillation/flutter, and for non‑compensatory sinus tachycardia in adults. Not for chronic use.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for METARAMINOL PHEBRA metaraminol (as tartrate) 10 mg/20 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LIDOCAINE 2.0% WITH ADRENALINE 1:200,000 PHEBRA lidocaine hydrochloride 400 mg/20 mL with adrenaline 100 microgram/20 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LIDOCAINE 1.0% WITH ADRENALINE 1:200,000 PHEBRA lidocaine hydrochloride 200 mg/20 mL with adrenaline 100 microgram/20 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LIDOCAINE 0.5% WITH ADRENALINE 1:200,000 PHEBRA lidocaine hydrochloride 100 mg/20 mL with adrenaline 100 microgram/20 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PAPAVERINE PHEBRA papaverine hydrochloride 120 mg/10 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RAPIBLYK landiolol hydrochloride 300 mg powder for injection vial.
-
Prescription medicine registrationActive ingredients: adrenaline (epinephrine) acid tartrate, lidocaine hydrochloride monohydrate.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for GLYCERYL TRINITRATE CONCENTRATED INJECTION PHEBRA glyceryl trinitrate 50 mg/10 mL concentrated injection vial.
-
Prescription medicine registrationActive ingredients: papaverine hydrochloride.